Medirom Healthcare Technologies Inc. current report, Q1 FY2022

Filing Overview

Medirom Healthcare Technologies Inc. filed a Form 6-K for March 2022 on March 30, 2022. The filing reports that the company issued a press release on March 29, 2022 regarding the results of its 22nd Ordinary General Meeting of Shareholders, held that day.

Business Context and Reporting Period

The filing concerns a corporate governance event rather than periodic financial results. The company is a foreign private issuer headquartered in Tokyo, Japan, and files annual reports on Form 20-F.

Financial and Operating Metrics

The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.

Material Changes and Shareholder Meeting Results

The filing states that the results of the 22nd Ordinary General Meeting were announced in Exhibit 99.1. The provided filing text does not include the underlying press release or a clear description of the resolutions, voting outcomes, director appointments, or other meeting results.

Outlook, Risks, and Unusual Items

  • The filing includes customary forward-looking statement language concerning plans, objectives, strategies, future events, and performance.
  • Management cautions that forward-looking statements rely on assumptions subject to significant uncertainties and contingencies beyond the company’s control.
  • The press release is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act and is not subject to the liabilities of that section.

Key Facts to Verify

  • Obtain and review Exhibit 99.1 to confirm the specific results and resolutions of the March 29, 2022 shareholder meeting.
  • Verify any director elections, auditor appointments, compensation matters, amendments, or other shareholder approvals reported in the press release.
  • Consult the company’s applicable Form 20-F or other financial filings for financial performance, liquidity, debt, and outlook information, which are not provided here.